The Asia Pacific Cataract Surgery Devices Market would witness market growth of 6.1% CAGR during the forecast period (2018 – 2024). Cataract surgery devices are majorly used in surgical procedures that are focused on treating cataract, an eye disorder which clouds the lens, and as a result, leads to defects in vision. Cataract is among the most common diseases which leads to blindness, reducing vision ability. Cataract is known to develop slowly and affects either one or both the eyes. Cataract does not directly interfere with the eyesight in its early stages; nevertheless, it interferes with vision and leads blindness over the years. Increase in incidences of diseases such as diabetes, obesity, hypertension and growth in geriatric population contributes to the growth of the market.
Based on Type, the market is segmented into Consumables and Equipment. Based on Product, the market is segmented into Ophthalmic Viscoelastic Device (OVD), Intraocular Lens (IOL) and Phacoemulsification Equipment. Based on End User, the market is segmented into Hospitals, Ambulatory Surgery Centers (ASCs) and Ophthalmology Clinics. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis Ag, Abbott Laboratories, Carl Zeiss Meditec Ag, Essilor International S.A, Johnson & Johnson, Metall Zug AG, Topcon Corporation, Nidek Co., Ltd, Valeant Pharmaceuticals International, Inc. and Ziemer Ophthalmic Systems Ag.